DUXAP8 and kidney neoplasm: For example, recent studies have found that CDKN2B-AS1 can be used as a biomarker for poor prognosis of kidney neoplasms (Angenard et al., 2019), DUXAP8 enhances the progression of kidney neoplasms by downregulating miR-126 (Huang et al., 2018), and HOTAIRM1 is downregulated in kidney neoplasms and inhibits hypoxia (Hamilton et al., 2020).